US2003139382A1PendingUtilityA1

Method of treating middle ear infections

Assignee: ALCON INCPriority: Sep 21, 2001Filed: Sep 13, 2002Published: Jul 24, 2003
Est. expirySep 21, 2021(expired)· nominal 20-yr term from priority
A61P 43/00A61K 9/10A61K 31/56A61P 31/04A61K 9/0046A61P 27/16A61K 47/02A61K 47/32A61K 31/496A61K 31/573A61K 31/57A61K 31/495A61P 31/00A61K 47/12A61K 47/38A61K 31/545
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Aqueous suspension formulations containing dexamethasone and ciprofloxacin are disclosed for the treatment of middle ear infections in human patients having an open tympanic membrane.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method of treating a middle ear infection in a human patient comprising the steps of: 
 (a) diagnosing the patient as having otitis media and an open tympanic membrane in at least one ear; and    (b) topically applying into the ear canal of the patient's ear an aqueous suspension composition containing a combination of ciprofloxacin and dexamethasone.    
     
     
         2 . The method of  claim 1  wherein the aqueous suspension composition comprises 
 a) 0.01-0.5% (wt.) dexamethasone;  
 b) 0.1-0.4% (wt.) ciprofloxacin;  
 c) a tonicity agent consisting essentially of NaCl in an amount sufficient to cause the composition to have an osmolality of about 250-350 mOsm;  
 d) 0.1-0.5% (wt.) of a nonionic polymer;  
 e) 0.01-0.2% (wt.) of a nonionic surfactant; and  
 f) a buffer,  
 wherein the composition has a pH from about 3-5.  
 
     
     
         3 . The method of  claim 1  wherein the dexamethasone is dexamethasone alcohol and the ciprofloxacin is ciprofloxacin hydrochloride, monohydrate.  
     
     
         4 . The method of  claim 1  wherein the aqueous suspension composition contains 0.1% (wt.) dexamethasone and 0.3% (wt.) ciprofloxacin.  
     
     
         5 . The method of  claim 4  wherein three or four drops of the aqueous suspension composition are administered to the patient's ear twice a day, wherein each drop is 30-35 μL.  
     
     
         6 . The method of  claim 1  wherein the aqueous suspension composition consists essentially of 
 a) 0.1% (wt.) dexamethasone alcohol;  
 b) 0.35% (wt.) ciprofloxacin hydrochloride, monohydrate;  
 c) NaCl in an amount sufficient to cause the composition to have an osmolality of about 250-350 mOsm;  
 d) 0.2% (wt.) hydroxyethyl cellulose;  
 e) 0.05% (wt.) tyloxapol;  
 f) a buffer comprising sodium acetate and acetic acid;  
 g) 0.01% (wt.) benzalkonium chloride;  
 h) 0.01% (wt.) edetate disodium;  
 i) 0.6% (wt.) boric acid; and  
 wherein the composition has a pH of about 4.5.  
 
     
     
         7 . The method of  claim 1  wherein the method further comprises the step of pumping the tragus to force the aqueous suspension composition through the open tympanic membrane and into the middle ear.  
     
     
         8 . The method of  claim 1  wherein the dexamethasone has an average particle size on a mean volume basis of less than 3 μm.  
     
     
         9 . The method of  claim 1  wherein the otitis media is acute otitis media.  
     
     
         10 . The method of  claim 1  wherein the otitis media is chronic supprative otitis media.  
     
     
         11 . The method of  claim 1  wherein the aqueous suspension composition containing a combination of ciprofloxacin and dexamethasone is packaged with directions for use that indicate the composition may be used to treat otitis media in patients with an open tympanic membrane.

Join the waitlist — get patent alerts

Track US2003139382A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.